U.S., Aug. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07787728) titled 'Phase Ib Clinical Study of MWN109 Injection in Participants With Overweight or Obesity' on Aug. 24.
Brief Summary: This study is a randomized, double-blind, placebo-controlled, multiple-dose phase Ib clinical trial, aiming to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity characteristics of MWN109 injection in Chinese non-diabetic participants with overweight or obesity.
A total of 40 participants were enrolled in the study. All participants were stratified and randomized by gender in blocks, and randomly assigned to 4 dose groups at a ratio of 1:1:1:1, with 10 participants in each group(8 ...